|

Surovatamig Clinical Trials

5 actively recruiting trials across 4 locations

▲ +1 trial since June 2026

Also known as: AZD0486, TNB-486

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • AstraZeneca5

Indications

  • Cancer4
  • B-Cell Non-Hodgkin Lymphoma2
  • Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV1
  • Large B-Cell Lymphoma (LBCL)1
  • Systemic Lupus Erythematosus1

Other1 trial

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Phase 3

Birmingham, Alabama1 trial

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Research Site

Phase 1

Huntsville, Alabama1 trial

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Research Site

Phase 3

Phoenix, Arizona1 trial

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Research Site

Phase 2

Boston, Massachusetts1 trial

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.